Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ananthsrinivas Chakilam

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical Sciences|August 11, 2007
Role of nanotechnology in pharmaceutical product developmentHarikrishna Devalapally, Ananthsrinivas Chakilam, Mansoor M Amiji
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 15, 2016
VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug InteractionsCraig Zetterberg, Francois Maltais, Leena Laitinen, et al.
Hepatology (Baltimore, Md.)|May 10, 2014
Telaprevir-based treatment effects on hepatitis C virus in liver and bloodAndrew H Talal, Rositsa B Dimova, Eileen Z Zhang, et al.
Experimental Biology and Medicine (Maywood, N.J.)|June 18, 2017
Navigating tissue chips from development to dissemination: A pharmaceutical industry perspectiveLorna Ewart, Kristin Fabre, Ananthsrinivas Chakilam, et al.
Journal of Medicinal Chemistry|August 1, 2015
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune DiseasesLuc J Farmer, Mark W Ledeboer, Thomas Hoock, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical Sciences|August 11, 2007
Role of nanotechnology in pharmaceutical product developmentHarikrishna Devalapally, Ananthsrinivas Chakilam, Mansoor M Amiji
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 15, 2016
VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug InteractionsCraig Zetterberg, Francois Maltais, Leena Laitinen, et al.
Hepatology (Baltimore, Md.)|May 10, 2014
Telaprevir-based treatment effects on hepatitis C virus in liver and bloodAndrew H Talal, Rositsa B Dimova, Eileen Z Zhang, et al.
Experimental Biology and Medicine (Maywood, N.J.)|June 18, 2017
Navigating tissue chips from development to dissemination: A pharmaceutical industry perspectiveLorna Ewart, Kristin Fabre, Ananthsrinivas Chakilam, et al.
Journal of Medicinal Chemistry|August 1, 2015
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune DiseasesLuc J Farmer, Mark W Ledeboer, Thomas Hoock, et al.
Pageof 1